This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Bristol Myers Squibb (BMY) Stock Moves -0.85%: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $68.77 in the latest trading session, marking a -0.85% move from the prior day.
FDA Nods to Bristol Myers' (BMY) Opdivo for Additional Indication
by Zacks Equity Research
Bristol Myers' (BMY) immuno-oncology Opdivo gets FDA nod for adult patients with resectable non-small cell lung cancer in the neoadjuvant setting in combination with platinum-doublet chemotherapy.
Do Options Traders Know Something About Bristol-Myers (BMY) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Bristol-Myers (BMY) stock based on the movements in the options market lately.
Mirati (MRTX) Q4 Earnings and Sales Fall Short of Estimates
by Zacks Equity Research
Mirati Therapeutics (MRTX) reports wider-than-expected fourth-quarter loss. Sales miss estimates.
Biohaven's (BHVN) Q4 Earnings Miss, Nurtec Gets CHMP Nod
by Zacks Equity Research
Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine, continues to demonstrate strong demand in the United States. The CHMP recommends approval of Nurtec ODT. Stock declines.
Iovance (IOVA) Announces Wider-Than-Anticipated Q4 Loss
by Zacks Equity Research
Iovance Biotherapeutics' (IOVA) fourth-quarter loss is wider than expected. The company is on track to file regulatory submission for lifileucel in melanoma by first-half 2022.
Clovis (CLVS) Q4 Loss Narrower than Expected, Revenues Lag
by Zacks Equity Research
Clovis (CLVS) reports narrower-than-expected loss for fourth-quarter 2021. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.
Exelixis (EXEL) Q4 Earnings & Revenues Beat, Cabometyx Strong
by Zacks Equity Research
Exelixis (EXEL) beats on both earnings and revenues in the fourth quarter. Both figures increase on a year-over-year basis.
Bristol Myers' (BMY) Breyanzi sBLA Gets FDA's Priority Review
by Zacks Equity Research
The FDA accepts Bristol Myers' (BMY) sBLA for Breyanzi under a priority review as a second-line treatment for relapsed/refractory large B-cell lymphoma. A decision is due on Jun 24, 2022.
Prothena (PRTA) Q4 Earnings Beat, Pipeline Progress in Focus
by Zacks Equity Research
Prothena beats on earnings and revenues in the fourth quarter of 2021. The company's progress with its AD pipeline is encouraging.
Zacks Industry Outlook Highlights: Sanofi, AbbVie, Bristol-Myers, Amgen and Vertex Pharmaceuticals
by Zacks Equity Research
Sanofi, AbbVie, Bristol-Myers, Amgen and Vertex Pharmaceuticals are highlighted in this Industry Outlook article.
Will the Rally of These 5 Big Drugmakers Continue in 2022?
by Zacks Equity Research
Here we discuss five big pharma/biotech companies - SNY, ABBV, BMY, AMGN and VRTX - with the potential to drive investors' wealth higher in 2022 on the back of strong fundamentals.
Biotech Stock Roundup: BMY, AMGN, REGN, BIIB's Q4 Earnings & More
by Zacks Equity Research
Earnings updates from Bristol-Myers (BMY), Amgen (AMGN) and others are among the few key highlights from the biotech sector during the past week.
How Will Pfizer's (PFE) Key Drugs Perform in Q4 Earnings?
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Eliquis (alliance revenue), Xtandi and Inlyta, and revenues from the COVID-19 vaccine are likely to have driven sales in the fourth quarter.
Bristol-Myers (BMY) Q4 Earnings Meet Estimates, Sales Beat
by Zacks Equity Research
Bristol-Myers (BMY) earnings match estimates in the fourth quarter of 2021, while sales beat the same on the back of Eliquis and Opdivo.
Bristol Myers Squibb (BMY) Q4 Earnings Meet Estimates
by Zacks Equity Research
Bristol Myers (BMY) delivered earnings and revenue surprises of 0% and 0.19%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stock Q4 Earnings Due on Feb 4: BMY, REGN & SNY
by Sundeep Ganoria
Let us take a look at three biotech/pharma companies ¿¿¿ BMY, REGN and SNY ¿¿¿ that are slated to release quarterly results on Feb 4.
Bristol-Myers (BMY) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Bristol-Myers' (BMY) Q4 earnings might have gained from strong demand for its multiple myeloma drug, Revlimid. Operating expenses might have jumped on costs associated with the broader portfolio.
Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $64.91 in the latest trading session, marking a +1.64% move from the prior day.
Bristol Myers Squibb (BMY) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merck (MRK) Keytruda Gets EU Nod for Expanded Kidney Cancer Use
by Zacks Equity Research
Following EU nod, Merck's (MRK) Keytruda is now approved as an adjuvant therapy for renal cell carcinoma in certain adult patients who are at an increased risk of recurrence, following nephrectomy.
Bristol Myers Squibb (BMY) Stock Moves -1.61%: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed the most recent trading day at $63.54, moving -1.61% from the previous trading session.
Bristol Myers Squibb (BMY) Stock Moves -0.26%: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed the most recent trading day at $64.72, moving -0.26% from the previous trading session.
Bristol Myers Squibb (BMY) Stock Moves -0.34%: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $64.60, marking a -0.34% move from the previous day.
Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $64.82, marking a -1.01% move from the previous day.